US and UK Finalize Duty-Free Accord on Prescription Drugs.

The United Kingdom and the United States have established a major commercial pact that will ensure zero duties on UK pharmaceutical exports going into the US market.

The Terms of the Deal

Under the terms of the agreement, the UK has agreed to raise funding on drugs through the public health system. This commitment guarantees that tariffs on these vital goods will remain at nothing for a duration of 36 months.

This development is in response to previous threats to significantly raise duties on patented drug products, with increases floated as high as one hundred percent.

"This deal between the Britain bolsters the international landscape for new treatments and introduces long-overdue equity to American-British pharmaceutical trade," an announcement declared.

Trade Impact

Pharmaceuticals are one of the Britain's biggest export categories to the US, which is clearly the biggest market for large companies like GSK and AstraZeneca.

Statistics indicate that in the one-year period leading up to the third quarter, the UK sold drugs worth billions to the US. This figure represented a significant portion of total UK exports in that period.

"This agreement secures jobs, increases capital expenditure and paves the way for the UK to emerge as a global hub for biotech and pharma," the Business and Trade Secretary commented.

Key NHS Changes

The pact includes several key changes from the United Kingdom:

• Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new therapies to be too expensive by 25%.
• Higher Drug Budget: There is a target to double overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the next decade.
• Rebate Cap: The amount drug companies must pay back to the NHS to control costs will be capped at fifteen percent. Last year, refunds exceeded 20%.

Industry Background

The pact comes amid a long-running dispute between the drug companies and the UK government over medicine costs and NHS adoption.

The disagreement were intensified by claims that US customers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.

In recent months, several major manufacturing plans in the UK have been halted or abandoned, while major expansions have been announced toward projects in the United States.

One official acknowledged that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the previous ten-year period.